The University of Southampton
University of Southampton Institutional Repository

Very early invasive angiography versus standard of care in higher-risk non-ST elevation myocardial infarction: study protocol for the prospective multicentre randomised controlled RAPID N-STEMI trial

Very early invasive angiography versus standard of care in higher-risk non-ST elevation myocardial infarction: study protocol for the prospective multicentre randomised controlled RAPID N-STEMI trial
Very early invasive angiography versus standard of care in higher-risk non-ST elevation myocardial infarction: study protocol for the prospective multicentre randomised controlled RAPID N-STEMI trial
Background: there are a paucity of randomised data on the optimal timing of invasive coronary angiography (ICA) in higher-risk patients with non-ST elevation myocardial infarction (N-STEMI). International guideline recommendations for early ICA are primarily based on retrospective subgroup analyses of neutral trials.

Aims: the RAPID N-STEMI trial aims to determine whether very early percutaneous revascularisation improves clinical outcomes as compared with a standard of care strategy in higher-risk N-STEMI patients.

Methods and analysis: RAPID N-STEMI is a prospective, multicentre, open-label, randomised-controlled, pragmatic strategy trial. Higher-risk N-STEMI patients, as defined by Global Registry of Acute Coronary Events 2.0 score ≥118, or >90 with at least one additional high-risk feature, were randomised to either: very early ICA±revascularisation or standard of care timing of ICA±revascularisation. The primary outcome is the proportion of participants with at least one of the following events (all-cause mortality, non-fatal myocardial infarction and hospital admission for heart failure) at 12 months. Key secondary outcomes include major bleeding and stroke. A hypothesis generating cardiac magnetic resonance (CMR) substudy will provide mechanistic data on infarct size, myocardial salvage and residual ischaemia post percutaneous coronary intervention. On 7 April 2021, the sponsor discontinued enrolment due to the impact of the COVID-19 pandemic and lower than expected event rates. 425 patients were enrolled, and 61 patients underwent CMR.

Ethics and dissemination: the trial has been reviewed and approved by the East of England Cambridge East Research Ethics Committee (18/EE/0222). The study results will be submitted for publication within 6 months of completion.

Trial registration number: NCT03707314; Pre-results.
2044-6055
Kite, Thomas A.
d18787aa-71ca-41db-8ced-c1db08dd8150
Banning, Amerjeet S.
4e8eb956-5e22-4cb9-9dd5-2901e6530969
Ladwiniec, Andrew
5659d0ac-43d3-4956-a9a6-36570f5eee62
Gale, Chris P.
25773e5f-b91f-4b1d-8a3a-6f4efbf8268a
Greenwood, John P.
8a764558-74f3-4639-aedd-fd775700fd6a
Dalby, Miles
0296ef2f-0e85-41da-974c-2e709b9494c6
Hobson, Rachel
d440e4d2-d6e4-4753-9d48-bb7313661012
Barber, Shaun
242add66-b589-4427-8a6b-6fb458d4c723
Parker, Emma
fb1f220e-8edf-48c1-a00a-c87bd05bd9a8
Berry, Colin
dbbcf211-52a9-45de-95d6-87a52f78791b
Flather, Marcus D.
b06ce11e-39a2-473d-96d0-7478c8d05419
Curzen, Nick
70f3ea49-51b1-418f-8e56-8210aef1abf4
Banning, Adrian P.
63c9376f-08b6-4578-b036-4d6233545270
McCann, Gerry P.
058e9548-9b74-48c0-a1e6-8d3cdb2f8369
Gershlick, Anthony H.
5beb7f92-68f7-41df-ba72-ef3d2cdf20b9
Kite, Thomas A.
d18787aa-71ca-41db-8ced-c1db08dd8150
Banning, Amerjeet S.
4e8eb956-5e22-4cb9-9dd5-2901e6530969
Ladwiniec, Andrew
5659d0ac-43d3-4956-a9a6-36570f5eee62
Gale, Chris P.
25773e5f-b91f-4b1d-8a3a-6f4efbf8268a
Greenwood, John P.
8a764558-74f3-4639-aedd-fd775700fd6a
Dalby, Miles
0296ef2f-0e85-41da-974c-2e709b9494c6
Hobson, Rachel
d440e4d2-d6e4-4753-9d48-bb7313661012
Barber, Shaun
242add66-b589-4427-8a6b-6fb458d4c723
Parker, Emma
fb1f220e-8edf-48c1-a00a-c87bd05bd9a8
Berry, Colin
dbbcf211-52a9-45de-95d6-87a52f78791b
Flather, Marcus D.
b06ce11e-39a2-473d-96d0-7478c8d05419
Curzen, Nick
70f3ea49-51b1-418f-8e56-8210aef1abf4
Banning, Adrian P.
63c9376f-08b6-4578-b036-4d6233545270
McCann, Gerry P.
058e9548-9b74-48c0-a1e6-8d3cdb2f8369
Gershlick, Anthony H.
5beb7f92-68f7-41df-ba72-ef3d2cdf20b9

Kite, Thomas A., Banning, Amerjeet S., Ladwiniec, Andrew, Gale, Chris P., Greenwood, John P., Dalby, Miles, Hobson, Rachel, Barber, Shaun, Parker, Emma, Berry, Colin, Flather, Marcus D., Curzen, Nick, Banning, Adrian P., McCann, Gerry P. and Gershlick, Anthony H. (2022) Very early invasive angiography versus standard of care in higher-risk non-ST elevation myocardial infarction: study protocol for the prospective multicentre randomised controlled RAPID N-STEMI trial. BMJ Open, 12 (5), [e055878]. (doi:10.1136/bmjopen-2021-055878).

Record type: Article

Abstract

Background: there are a paucity of randomised data on the optimal timing of invasive coronary angiography (ICA) in higher-risk patients with non-ST elevation myocardial infarction (N-STEMI). International guideline recommendations for early ICA are primarily based on retrospective subgroup analyses of neutral trials.

Aims: the RAPID N-STEMI trial aims to determine whether very early percutaneous revascularisation improves clinical outcomes as compared with a standard of care strategy in higher-risk N-STEMI patients.

Methods and analysis: RAPID N-STEMI is a prospective, multicentre, open-label, randomised-controlled, pragmatic strategy trial. Higher-risk N-STEMI patients, as defined by Global Registry of Acute Coronary Events 2.0 score ≥118, or >90 with at least one additional high-risk feature, were randomised to either: very early ICA±revascularisation or standard of care timing of ICA±revascularisation. The primary outcome is the proportion of participants with at least one of the following events (all-cause mortality, non-fatal myocardial infarction and hospital admission for heart failure) at 12 months. Key secondary outcomes include major bleeding and stroke. A hypothesis generating cardiac magnetic resonance (CMR) substudy will provide mechanistic data on infarct size, myocardial salvage and residual ischaemia post percutaneous coronary intervention. On 7 April 2021, the sponsor discontinued enrolment due to the impact of the COVID-19 pandemic and lower than expected event rates. 425 patients were enrolled, and 61 patients underwent CMR.

Ethics and dissemination: the trial has been reviewed and approved by the East of England Cambridge East Research Ethics Committee (18/EE/0222). The study results will be submitted for publication within 6 months of completion.

Trial registration number: NCT03707314; Pre-results.

Text
e055878.full - Version of Record
Available under License Creative Commons Attribution.
Download (523kB)

More information

Accepted/In Press date: 24 February 2022
Published date: 3 May 2022

Identifiers

Local EPrints ID: 492653
URI: http://eprints.soton.ac.uk/id/eprint/492653
ISSN: 2044-6055
PURE UUID: 80d00e32-1daf-4666-aa03-e63d283b5eaa
ORCID for Nick Curzen: ORCID iD orcid.org/0000-0001-9651-7829

Catalogue record

Date deposited: 09 Aug 2024 16:42
Last modified: 10 Aug 2024 01:40

Export record

Altmetrics

Contributors

Author: Thomas A. Kite
Author: Amerjeet S. Banning
Author: Andrew Ladwiniec
Author: Chris P. Gale
Author: John P. Greenwood
Author: Miles Dalby
Author: Rachel Hobson
Author: Shaun Barber
Author: Emma Parker
Author: Colin Berry
Author: Marcus D. Flather
Author: Nick Curzen ORCID iD
Author: Adrian P. Banning
Author: Gerry P. McCann
Author: Anthony H. Gershlick

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×